Research Hotspots in Psoriasis: A Bibliometric Study of the Top 100 Most Cited Articles
Abstract
1. Introduction
2. Material and Methods
2.1. Search Strategy and Data Collection
2.2. Bibliometric Analysis
3. Results
3.1. Citation Analysis
3.2. Co-Authorship Analysis
3.3. Co-Word Analysis
3.4. Bibliographical Coupling
3.5. Co-Citation Analysis
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- WHO Organization. Global Report on Psoriasis; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
- Damiani, G.; Bragazzi, N.L.; Karimkhani Aksut, C.; Wu, D.; Alicandro, G.; McGonagle, D.; Guo, C.; Dellavalle, R.; Grada, A.; Wong, P.; et al. The global, regional, and national burden of psoriasis: Results and insights from the global burden of disease 2019 Study. Front. Med. 2021, 8, 743180. [Google Scholar] [CrossRef]
- Mahil, S.K.; Capon, F.; Barker, J.N. Genetics of psoriasis. Dermatol. Clin. 2015, 33, 1–11. [Google Scholar] [CrossRef]
- Zeng, J.; Luo, S.; Huang, Y.; Lu, Q. Critical role of environmental factors in the pathogenesis of psoriasis. J. Dermatol. 2017, 44, 863–872. [Google Scholar] [CrossRef]
- Gisondi, P.; Fostini, A.C.; Fossà, I.; Girolomoni, G.; Targher, G. Psoriasis and the metabolic syndrome. Clin. Dermatol. 2018, 36, 21–28. [Google Scholar] [CrossRef]
- Xiaohong, L.; Zhenting, Z.; Yunjie, Y.; Wei, C.; Xiangjin, X.; Kun, X.; Xin, L.; Lu, L.; Jun, L.; Pin, C. Activation of the sting-irf3 pathway involved in psoriasis with diabetes mellitus. J. Cell. Mol. Med. 2022, 26, 2139–2151. [Google Scholar] [CrossRef]
- Pritchard, A. Statistical Bibliography or Bibliometrics? J. Doc. 1969, 25, 348–349. [Google Scholar]
- Stremersch, S.; Verniers, I.; Verhoef, P.C. The quest for citations: Drivers of article impact. J. Mark. 2007, 71, 171–193. [Google Scholar] [CrossRef]
- Fan, K.S.; Fan, K.H.; Tse, P.L.; Ding, H.; Su, R.; Kwok, H.T. Analysis of top-cited articles on melanoma. Acta Dermatovenerol. Alp. Pannonica Adriat. 2022, 31, 127–133. [Google Scholar] [CrossRef]
- Kwok, H.T.; Van, M.; Fan, K.S.; Chan, J. Top 100 cited articles in male breast cancer: A bibliometric analysis. Breast Dis. 2022, 41, 15–20. [Google Scholar] [CrossRef]
- Zhang, Y.; Yu, C. Bibliometric evaluation of publications (2000–2020) on the prognosis of gastric cancer. Inquiry 2021, 58, 469580211056015. [Google Scholar] [CrossRef] [PubMed]
- Joyce, C.W.; Sugrue, C.M.; Joyce, K.M.; Kelly, J.L.; Regan, P.J. 100 citation classics in the melanoma literature: A bibliometric analysis. Dermatol. Surg. 2014, 40, 1284–1298. [Google Scholar] [CrossRef] [PubMed]
- Cocuz, I.G.; Cocuz, M.E.; Repanovici, A.; Sabău, A.-H.; Niculescu, R.; Tinca, A.-C.; Vunvulea, V.; Budin, C.E.; Szoke, A.R.; Popelea, M.C.; et al. Scientific research directions on the histopathology and immunohistochemistry of the cutaneous squamous cell carcinoma: A scientometric study. Medicina 2022, 58, 1449. [Google Scholar] [CrossRef]
- Paladugu, R.; Schein, M.; Gardezi, S.; Wise, L. One hundred citation classics in general surgical journals. World J. Surg. 2002, 26, 1099–1105. [Google Scholar] [CrossRef]
- Strange, A.; Capon, F.; Spencer, C.C.A.; Knight, J.; Weale, M.E.; Allen, M.H.; Barton, A.; Band, G.; Bellenguez, C.; Bergboer, J.G.M.; et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet 2010, 42, 985–990. [Google Scholar]
- Papp, K.; Tyring, S.; Lahfa, M.; Prinz, J.; Griffiths, C.; Nakanishi, A.; Zitnik, R.; van de Kerkhof, P.; Grp, E.P.S. A global phase iii randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 2005, 152, 1304–1312. [Google Scholar] [CrossRef]
- Cargill, M.; Schrodi, S.J.; Chang, M.; Garcia, V.E.; Brandon, R.; Callis, K.P.; Matsunami, N.; Ardlie, K.G.; Civello, D.; Catanese, J.J.; et al. A large-scale genetic association study confirms il12b and leads to the identification of il23r as psoriasis-risk genes. Am. J. Hum. Genet 2007, 80, 273–290. [Google Scholar] [CrossRef]
- Krueger, G.G.; Langley, R.G.; Leonardi, C.; Yeilding, N.; Guzzo, C.; Wang, Y.; Dooley, L.T.; Lebwohl, M.; Grp, C. 1275 P. S. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 2007, 356, 580–592. [Google Scholar] [CrossRef]
- Lebwohl, M.; Tyring, S.; Hamilton, T.; Toth, D.; Glazer, S.; Tawfik, N.; Walicke, P.; Dummer, W.; Wang, X.; Garovoy, M.; et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 2003, 349, 2004–2013. [Google Scholar] [CrossRef]
- Michalek, I.M.; Loring, B.; John, S.M. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 205–212. [Google Scholar] [CrossRef]
- Menter, A.; Tyring, S.K.; Gordon, K.; Kimball, A.B.; Leonardi, C.L.; Langley, R.G.; Strober, B.E.; Kaul, M.; Gu, Y.; Okun, M.; et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase iii trial. J. Am. Acad. Dermatol. 2008, 58, 106–115. [Google Scholar] [CrossRef]
- Leonardi, C.; Matheson, R.; Zachariae, C.; Cameron, G.; Li, L.; Edson-Heredia, E.; Braun, D.; Banerjee, S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012, 366, 1190–1199. [Google Scholar] [CrossRef]
- Nickoloff, B.; Karabin, G.; Barker, J.; Griffiths, C.; Sarma, V.; Mitra, R.; Elder, J.; Kunkel, S.; Dixit, V. Cellular-localization of interleukin-8 and its inducer, tumor-necrosis-factor-alpha in psoriasis. Am. J. Pathol. 1991, 138, 129–140. [Google Scholar]
- Wada, Y.; Cardinale, I.; Khatcherian, A.; Chu, J.; Kantor, A.B.; Gottlieb, A.B.; Tatsuta, N.; Jacobson, E.; Barsoum, J.; Krueger, J.G. Apilimod inhibits the production of il-12 and il-23 and reduces dendritic cell infiltration in psoriasis. PLoS ONE 2012, 7, e35069. [Google Scholar] [CrossRef]
- Papp, K.A.; Leonardi, C.; Menter, A.; Ortonne, J.-P.; Krueger, J.G.; Kricorian, G.; Aras, G.; Li, J.; Russell, C.B.; Thompson, E.H.Z.; et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 2012, 366, 1181–1189. [Google Scholar] [CrossRef]
- Naldi, L.; Chatenoud, L.; Linder, D.; Fortina, A.; Peserico, A.; Virgili, A.; Bruni, P.; Ingordo, V.; Lo Scocco, G.; Solaroli, C.; et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an italian case-control study. J. Investig. Dermatol. 2005, 125, 61–67. [Google Scholar] [CrossRef]
- Kagami, S.; Rizzo, H.L.; Lee, J.J.; Koguchi, Y.; Blauvelt, A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Investig. Dermatol. 2010, 130, 1373–1383. [Google Scholar] [CrossRef]
- Gordon, K.B.; Langley, R.G.; Leonardi, C.; Toth, D.; Menter, M.A.; Kang, S.; Heffernan, M.; Miller, B.; Hamlin, R.; Lim, L.; et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 2006, 55, 598–606. [Google Scholar] [CrossRef]
- Griffiths, C.E.M.; Reich, K.; Lebwohl, M.; van de Kerkhof, P.; Paul, C.; Menter, A.; Cameron, G.S.; Erickson, J.; Zhang, L.; Secrest, R.J.; et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet 2015, 386, 541–551. [Google Scholar] [CrossRef]
- Griffiths, C.E.M.; Strober, B.E.; van de Kerkhof, P.; Ho, V.; Fidelus-Gort, R.; Yeilding, N.; Guzzo, C.; Xia, Y.; Zhou, B.; Li, S.; et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 2010, 362, 118–128. [Google Scholar] [CrossRef]
- Abrams, J.; Lebwohl, M.; Guzzo, C.; Jegasothy, B.; Goldfarb, M.; Goffe, B.; Menter, A.; Lowe, N.; Krueger, G.; Brown, M.; et al. CTLA4ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Investig. 1999, 103, 1243–1252. [Google Scholar] [CrossRef]
- Ellis, C.; Gorsulowsky, D.; Hamilton, T.; Billings, J.; Brown, M.; Headington, J.; Cooper, K.; Baadsgaard, O.; Duell, E.; Annesley, T.; et al. Cyclosporine improves psoriasis in a double-blind-study. JAMA-J. Am. Med. Assoc. 1986, 256, 3110–3116. [Google Scholar] [CrossRef]
- Mrowietz, U.; Kragballe, K.; Reich, K.; Spuls, P.; Griffiths, C.E.M.; Nast, A.; Franke, J.; Antoniou, C.; Arenberger, P.; Balieva, F.; et al. Definition of treatment goals for moderate to severe psoriasis: A european consensus. Arch. Dermatol. Res. 2011, 303, 1–10. [Google Scholar] [CrossRef]
- Henseler, T.; Christophers, E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 1995, 32, 982–986. [Google Scholar] [CrossRef]
- Sugiyama, H.; Gyulai, R.; Toichi, E.; Garaczi, E.; Shimada, S.; Stevens, S.; McCormick, T.; Cooper, K. Dysfunctional blood and target tissue CD4(+)CD25(high) regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector t cell proliferation. J. Immunol. 2005, 174, 164–173. [Google Scholar] [CrossRef]
- Blauvelt, A.; Papp, K.A.; Griffiths, C.E.M.; Randazzo, B.; Wasfi, Y.; Shen, Y.-K.; Li, S.; Kimball, A.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase iii, double-blinded, placebo- and active comparatore-controlled voyage 1 trial. J. Am. Acad. Dermatol. 2017, 76, 405–417. [Google Scholar]
- Reich, K.; Armstrong, A.W.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Li, S.; Shen, Y.K.; Gordon, K.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase iii, double-blind, placebo- and active comparatore-controlled voyage 2 trial. J. Am. Acad. Dermatol. 2017, 76, 418–431. [Google Scholar]
- McInnes, I.B.; Kavanaugh, A.; Gottlieb, A.B.; Puig, L.; Rahman, P.; Ritchlin, C.; Brodmerkel, C.; Li, S.; Wang, Y.; Mendelsohn, A.M.; et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled psummit 1 trial. Lancet 2013, 382, 780–789. [Google Scholar] [CrossRef]
- Chaudhari, U.; Romano, P.; Mulcahy, L.; Dooley, L.; Baker, D.; Gottlieb, A. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001, 357, 1842–1847. [Google Scholar] [CrossRef]
- Papp, K.A.; Langley, R.G.; Lebwohl, M.; Krueger, G.G.; Szapary, P.; Yeilding, N.; Guzzo, C.; Hsu, M.-C.; Wang, Y.; Li, S.; et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2). Lancet 2008, 371, 1675–1684. [Google Scholar] [CrossRef]
- Leonardi, C.L.; Kimball, A.B.; Papp, K.A.; Yeilding, N.; Guzzo, C.; Wang, Y.; Li, S.; Dooley, L.T.; Gordon, K.B.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (phoenix 1). Lancet 2008, 371, 1665–1674. [Google Scholar] [CrossRef]
- Tyring, S.; Gottlieb, A.; Papp, K.; Gordon, K.; Leonardi, C.; Wang, A.; Lalla, D.; Woolley, M.; Jahreis, A.; Zitnik, R.; et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367, 29–35. [Google Scholar] [CrossRef]
- Saurat, J.-H.; Stingl, G.; Dubertret, L.; Papp, K.; Langley, R.G.; Ortonne, J.-P.; Unnebrink, K.; Kaul, M.; Camez, A.; Invest, C.S. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. Methotrexate vs. Placebo in patients with psoriasis (champion). Br. J. Dermatol. 2008, 158, 558–566. [Google Scholar] [CrossRef]
- Leonardi, C.; Powers, J.; Matheson, R.; Goffe, B.; Zitnik, R.; Wang, A.; Gottlieb, A.; Bagel, J.; Camisa, C.; Caro, I.; et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 2003, 349, 2014–2022. [Google Scholar] [CrossRef]
- Baker, H.; Ryan, T. Generalized pustular psoriasis—A clinical and epidemiological study of 104 cases. Br. J. Dermatol. 1968, 80, 771–793. [Google Scholar] [CrossRef]
- Pathirana, D.; Ormerod, A.D.; Saiag, P.; Smith, C.; Spuls, P.I.; Nast, A.; Barker, J.; Bos, J.D.; Burmester, G.-R.; Chimenti, S.; et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. 2009, 23, 5–70. [Google Scholar] [CrossRef]
- Nair, R.P.; Duffin, K.C.; Helms, C.; Ding, J.; Stuart, P.E.; Goldgar, D.; Gudjonsson, J.E.; Li, Y.; Tejasvi, T.; Feng, B.-J.; et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappa B pathways. Nat. Genet 2009, 41, 199–204. [Google Scholar] [CrossRef]
- Parisi, R.; Symmons, D.P.M.; Griffiths, C.E.M.; Ashcroft, D.M.; Management, I. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013, 133, 377–385. [Google Scholar] [CrossRef]
- Tsoi, L.C.; Spain, S.L.; Knight, J.; Ellinghaus, E.; Stuart, P.E.; Capon, F.; Ding, J.; Li, Y.; Tejasvi, T.; Gudjonsson, J.E.; et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet 2012, 44, 1341–1348. [Google Scholar] [CrossRef]
- Trembath, R.; Clough, R.; Rosbotham, J.; Jones, A.; Camp, R.; Frodsham, A.; Browne, J.; Barber, R.; Terwilliger, J.; Lathrop, G.; et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum. Mol. Genet 1997, 6, 813–820. [Google Scholar] [CrossRef]
- Ma, H.-L.; Liang, S.; Li, J.; Napierata, L.; Brown, T.; Benoit, S.; Senices, M.; Gill, D.; Dunussi-Joannopoulos, K.; Collins, M.; et al. Il-22 is required for th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Investig. 2008, 118, 597–607. [Google Scholar] [CrossRef]
- Wolk, K.; Witte, E.; Wallace, E.; Doecke, W.-D.; Kunz, S.; Asadullah, K.; Volk, H.-D.; Sterry, W.; Sabat, R. Il-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur. J. Immunol. 2006, 36, 1309–1323. [Google Scholar] [CrossRef]
- Chan, J.R.; Blumenschein, W.; Murphy, E.; Diveu, C.; Wiekowski, M.; Abbondanzo, S.; Lucian, L.; Geissler, R.; Brodie, S.; Kimball, A.B.; et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 2006, 203, 2577–2587. [Google Scholar] [CrossRef]
- van der Fits, L.; Mourits, S.; Voerman, J.S.A.; Kant, M.; Boon, L.; Laman, J.D.; Cornelissen, F.; Mus, A.-M.; Florencia, E.; Prens, E.P.; et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the Il-23/Il-17 Axis. J. Immunol. 2009, 182, 5836–5845. [Google Scholar] [CrossRef]
- Hammarstrom, S.; Hamberg, M.; Samuelsson, B.; Duell, E.; Stawiski, M.; Voorhees, J. Increased concentrations of nonesterified arachidonic-acid, 12l-Hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin-E2, and prostaglandin-F2alpha in epidermis of psoriasis. Proc. Natl. Acad. Sci. USA 1975, 72, 5130–5134. [Google Scholar] [CrossRef]
- Lowes, M.A.; Suarez-Farinas, M.; Krueger, J.G. Immunology of Psoriasis. Annu. Rev. Immunol. 2014, 32, 227–255. [Google Scholar] [CrossRef]
- Lee, E.; Trepicchio, W.; Oestreicher, J.; Pittman, D.; Wang, F.; Chamian, F.; Dhodapkar, M.; Krueger, J. Increased Expression of Interleukin 23 P19 and P40 in Lesional Skin of Patients with Psoriasis Vulgaris. J. Exp. Med. 2004, 199, 125–130. [Google Scholar] [CrossRef]
- Sommer, D.M.; Jenisch, S.; Suchan, M.; Christophers, E.; Weichenthal, M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006, 298, 321–328. [Google Scholar] [CrossRef]
- Gottlieb, A.; Evans, R.; Li, S.; Dooley, L.; Guzzo, C.; Baker, D.; Bala, M.; Marano, C.; Menter, A. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2004, 51, 534–542. [Google Scholar] [CrossRef]
- Reich, K.; Nestle, F.; Papp, K.; Ortonne, J.; Evans, R.; Guzzo, C.; Li, S.; Dooley, L.; Griffiths, C.; Investigators, E.S. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase iii, multicentre, double-blind trial. Lancet 2005, 366, 1367–1374. [Google Scholar] [CrossRef]
- Chiricozzi, A.; Guttman-Yassky, E.; Suarez-Farinas, M.; Nograles, K.E.; Tian, S.; Cardinale, I.; Chimenti, S.; Krueger, J.G. Integrative responses to il-17 and tnf-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Investig. Dermatol. 2011, 131, 677–687. [Google Scholar] [CrossRef]
- Zheng, Y.; Danilenko, D.M.; Valdez, P.; Kasman, I.; Eastham-Anderson, J.; Wu, J.; Ouyang, W. Interleukin-22, a t(h)17 cytokine, mediates il-23-induced dermal inflammation and acanthosis. Nature 2007, 445, 648–651. [Google Scholar] [CrossRef]
- Marrakchi, S.; Guigue, P.; Renshaw, B.R.; Puel, A.; Pei, X.-Y.; Fraitag, S.; Zribi, J.; Bal, E.; Cluzeau, C.; Chrabieh, M.; et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 2011, 365, 620–628. [Google Scholar] [CrossRef]
- Stern, R.; Nichols, K.; Vakeva, L. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet a radiation (puva). N. Engl. J. Med. 1997, 336, 1041–1045. [Google Scholar] [CrossRef]
- Lin, A.M.; Rubin, C.J.; Khandpur, R.; Wang, J.Y.; Riblett, M.; Yalavarthi, S.; Villanueva, E.C.; Shah, P.; Kaplan, M.J.; Bruce, A.T. Mast cells and neutrophils release il-17 through extracellular trap formation in psoriasis. J. Immunol. 2011, 187, 490–500. [Google Scholar] [CrossRef]
- Nestle, F.O.; Kaplan, D.H.; Barker, J. Mechanisms of disease: Psoriasis. N. Engl. J. Med. 2009, 361, 496–509. [Google Scholar] [CrossRef]
- Schon, M.; Boehncke, W. Medical Progress—Psoriasis. N. Engl. J. Med. 2005, 352, 1899–1912. [Google Scholar] [CrossRef]
- Sonkoly, E.; Wei, T.; Janson, P.C.J.; Saaf, A.; Lundeberg, L.; Tengvall-Linder, M.; Norstedt, G.; Alenius, H.; Homey, B.; Scheynius, A.; et al. Micrornas: Novel regulators involved in the pathogenesis of psoriasis? PLoS ONE 2007, 2, e610. [Google Scholar] [CrossRef]
- Farber, E.; Nall, M. Natural-History of Psoriasis in 5600 Patients. Dermatologica 1974, 148, 1–18. [Google Scholar] [CrossRef]
- Melski, J.; Tanenbaum, L.; Parrish, J.; Fitzpatrick, T.; Bleich, H. Oral methoxsalen photochemotherapy for treatment of psoriasis—Cooperative clinical-trial. J. Investig. Dermatol. 1977, 68, 328–335. [Google Scholar]
- Detmar, M.; Brown, L.; Claffey, K.; Yee, K.; Kocher, O.; Jackman, R.; Berse, B.; Dvorak, H. Overexpression of vascular-permeability factor vascular endothelial growth-factor and its receptors in psoriasis. J. Exp. Med. 1994, 180, 1141–1146. [Google Scholar] [CrossRef]
- Lowes, M.A.; Bowcock, A.M.; Krueger, J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445, 866–873. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis a review. JAMA-J. Am. Med. Assoc. 2020, 323, 1945–1960. [Google Scholar] [CrossRef]
- Mehta, N.N.; Azfar, R.S.; Shin, D.B.; Neimanns, A.L.; Troxel, A.B.; Gelfand, J.M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the general practice research database. Eur. Heart J. 2010, 31, 1000–1006. [Google Scholar] [CrossRef]
- Lebwohl, M.; Strober, B.; Menter, A.; Gordon, K.; Weglowska, J.; Puig, L.; Papp, K.; Spelman, L.; Toth, D.; Kerdel, F.; et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N. Engl. J. Med. 2015, 373, 1318–1328. [Google Scholar] [CrossRef]
- Gordon, K.B.; Blauvelt, A.; Papp, K.A.; Langley, R.G.; Luger, T.; Ohtsuki, M.; Reich, K.; Amato, D.; Ball, S.G.; Braun, D.K.; et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. 2016, 375, 345–356. [Google Scholar] [CrossRef]
- Parrish, J.; Fitzpatrick, T.; Tanenbaum, L.; Pathak, M. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet-light. N. Engl. J. Med. 1974, 291, 1207–1211. [Google Scholar] [CrossRef]
- Nestle, F.; Conrad, C.; Tun-Kyi, A.; Homey, B.; Gombert, M.; Boyman, O.; Burg, G.; Liu, Y.; Gilliet, M. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 2005, 202, 135–143. [Google Scholar] [CrossRef]
- Gelfand, J.; Weinstein, R.; Porter, S.; Neimann, A.; Berlin, J.; Margolis, D. Prevalence and treatment of psoriasis in the united kingdom—A population-based study. Arch. Dermatol. 2005, 141, 1537–1541. [Google Scholar] [CrossRef]
- Neimann, A.L.; Shin, D.B.; Wang, X.; Margolis, D.J.; Troxel, A.B.; Gelfand, J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006, 55, 829–835. [Google Scholar] [CrossRef]
- Boehncke, W.H.; Schoen, M.P. Psoriasis. Lancet 2015, 386, 983–994. [Google Scholar] [CrossRef]
- Gisondi, P.; Tessari, G.; Conti, A.; Piaserico, S.; Schianchi, S.; Peserico, A.; Giannetti, A.; Girolomoni, G. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br. J. Dermatol. 2007, 157, 68–73. [Google Scholar] [CrossRef]
- Greb, J.E.; Goldminz, A.M.; Elder, J.T.; Lebwohl, M.G.; Gladman, D.D.; Wu, J.J.; Mehta, N.N.; Finlay, A.Y.; Gottlieb, A.B. Psoriasis. Nat. Rev. Dis. Prim. 2016, 2, 16082. [Google Scholar] [CrossRef]
- Lebwohl, M. Psoriasis. Lancet 2003, 361, 1197–1204. [Google Scholar] [CrossRef]
- Griffiths, C.; Barker, J. Psoriasis 1—Pathogenesis and clinical features of Psoriasis. Lancet 2007, 370, 263–271. [Google Scholar] [CrossRef]
- Christophers, E. Psoriasis—Epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26, 314–320. [Google Scholar] [CrossRef]
- Takeshita, J.; Grewal, S.; Langan, S.M.; Mehta, N.N.; Ogdie, A.; Van Voorhees, A.S.; Gelfand, J.M. Psoriasis and comorbid diseases epidemiology. J. Am. Acad. Dermatol. 2017, 76, 377–390. [Google Scholar] [CrossRef]
- Davidovici, B.B.; Sattar, N.; Joerg, P.C.; Puig, L.; Emery, P.; Barker, J.N.; van de Kerkhof, P.; Stahle, M.; Nestle, F.O.; Girolomoni, G.; et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J. Investig. Dermatol. 2010, 130, 1785–1796. [Google Scholar] [CrossRef]
- Rapp, S.; Feldman, S.; Exum, M.; Fleischer, A.; Reboussin, D. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 1999, 41, 401–407. [Google Scholar] [CrossRef]
- Hollox, E.J.; Huffmeier, U.; Zeeuwen, P.L.J.M.; Palla, R.; Lascorz, J.; Rodijk-Olthuis, D.; van de Kerkhof, P.C.M.; Traupe, H.; de Jongh, G.; den Heijer, M.; et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat. Genet 2008, 40, 23–25. [Google Scholar] [CrossRef]
- Stern, R.; Nijsten, T.; Feldman, S.; Margolis, D.; Rolstad, T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. 2004, 9, 136–139. [Google Scholar] [CrossRef]
- Henseler, T.; Christophers, E. Psoriasis of early and late onset—Characterization of 2 types of psoriasis-vulgaris. J. Am. Acad. Dermatol. 1985, 13, 450–456. [Google Scholar] [CrossRef]
- Hawkes, J.E.; Chan, T.C.; Krueger, J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J. Allergy Clin. Immunol. 2017, 140, 645–653. [Google Scholar] [CrossRef]
- Rendon, A.; Schaekel, K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019, 20, 1475. [Google Scholar] [CrossRef]
- Rachakonda, T.D.; Schupp, C.W.; Armstrong, A.W. Psoriasis prevalence among adults in The United States. J. Am. Acad. Dermatol. 2014, 70, 512–516. [Google Scholar] [CrossRef]
- Lowes, M.A.; Kikuchi, T.; Fuentes-Duculan, J.; Cardinale, I.; Zaba, L.C.; Haider, A.S.; Bowman, E.P.; Krueger, J.G. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Investig. Dermatol. 2008, 128, 1207–1211. [Google Scholar] [CrossRef]
- Zenz, R.; Eferl, R.; Kenner, L.; Florin, L.; Hummerich, L.; Mehic, D.; Scheuch, H.; Angel, P.; Tschachler, E.; Wagner, E. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of jun proteins. Nature 2005, 437, 369–375. [Google Scholar] [CrossRef]
- Langley, R.; Krueger, G.; Griffiths, C. Psoriasis: Epidemiology, clinical features, and quality of life. Ann. Rheum. Dis. 2005, 64, 18–23. [Google Scholar] [CrossRef]
- Nickoloff, B.; Nestle, F. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Investig. 2004, 113, 1664–1675. [Google Scholar] [CrossRef]
- Gottlieb, S.; Gilleaudeau, P.; Johnson, R.; Estes, L.; Woodworth, T.; Gottlieb, A.; Krueger, J. Response of psoriasis to a lymphocyte-selective toxin (dab(389)il-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1995, 1, 442–447. [Google Scholar] [CrossRef]
- Stern, R.; Thibodeau, L.; Kleinerman, R.; Parrish, J.; Fitzpatrick, T. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for Psoriasis. N. Engl. J. Med. 1979, 300, 809–813. [Google Scholar] [CrossRef]
- Gelfand, J.M.; Neimann, A.L.; Shin, D.B.; Wang, X.; Margolis, D.J.; Troxel, A.B. Risk of myocardial infarction in patients with psoriasis. JAMA-J. Am. Med. Assoc. 2006, 296, 1735–1741. [Google Scholar] [CrossRef]
- Langley, R.G.; Elewski, B.E.; Lebwohl, M.; Reich, K.; Griffiths, C.E.M.; Papp, K.; Puig, L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; et al. Secukinumab in plaque psoriasis—Results of two phase 3 trials. N. Engl. J. Med. 2014, 371, 326–338. [Google Scholar] [CrossRef]
- Nair, R.; Stuart, P.; Nistor, I.; Hiremagalore, R.; Chia, N.; Jenisch, S.; Weichenthal, M.; Abecasis, G.; Lim, H.; Christophers, E.; et al. Sequence and haplotype analysis supports hla-c as the psoriasis susceptibility 1 gene. Am. J. Hum. Genet 2006, 78, 827–851. [Google Scholar] [CrossRef]
- Arican, O.; Aral, M.; Sasmaz, S.; Ciragil, P. Serum Levels of TNF-Alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat. Inflamm. 2005, 2005, 273–279. [Google Scholar] [CrossRef]
- Fredriksson, T.; Pettersson, U. Severe psoriasis—Oral therapy with a new retinoid. Dermatologica 1978, 157, 238–244. [Google Scholar] [CrossRef]
- Sano, S.; Chan, K.; Carbajal, S.; Clifford, J.; Peavey, M.; Kiguchi, K.; Itami, S.; Nickoloff, B.; DiGiovanni, J. STATt3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 2005, 11, 43–49. [Google Scholar] [CrossRef]
- Nograles, K.E.; Zaba, L.C.; Guttman-Yassky, E.; Fuentes-Duculan, J.; Suarez-Farinas, M.; Cardinale, I.; Khatcherian, A.; Gonzalez, J.; Pierson, K.C.; White, T.R.; et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 2008, 159, 1092–1102. [Google Scholar] [CrossRef]
- Di Cesare, A.; Di Meglio, P.; Nestle, F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Investig. Dermatol. 2009, 129, 1339–1350. [Google Scholar] [CrossRef]
- Krueger, G.; Koo, J.; Lebwohl, M.; Menter, A.; Stern, R.; Rolstad, T. The impact of psoriasis on quality of life—Results of a 1998 national psoriasis foundation patient-membership survey. Arch. Dermatol. 2001, 137, 280–284. [Google Scholar]
- Krueger, J. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 2002, 46, 1–26. [Google Scholar] [CrossRef]
- Kurd, S.K.; Troxel, A.B.; Crits-Christoph, P.; Gelfand, J.M. The risk of depression, anxiety, and suicidality in patients with psoriasis a population-based cohort study. Arch. Dermatol. 2010, 146, 891–895. [Google Scholar]
- Ellis, C.; Krueger, G.; Grp, A.C.S. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 2001, 345, 248–255. [Google Scholar] [CrossRef]
- Homey, B.; Dieu-Nosjean, M.; Wiesenborn, A.; Massacrier, C.; Pin, J.; Oldham, E.; Catron, D.; Buchanan, M.; Muller, A.; Malefyt, R.; et al. Up-regulation of macrophage inflammatory protein-3 alpha/ccl20 and cc chemokine receptor 6 in psoriasis. J. Immunol. 2000, 164, 6621–6632. [Google Scholar] [CrossRef]
- Van Eck, N.J.; Waltman, L. Software Survey: Vosviewer, a computer program for bibliometric mapping. Scientometrics 2010, 84, 523–538. [Google Scholar] [CrossRef]
- Donthu, N.; Kumar, S.; Mukherjee, D.; Pandey, N.; Lim, W.M. How to conduct a bibliometric analysis: An overview and guidelines. J. Bus. Res. 2021, 133, 285–296. [Google Scholar] [CrossRef]
- Reid, C.; Griffiths, C.E.M. Psoriasis and treatment: Past, present and future aspects. Acta Dermatol. Venereol. 2020, 100, Adv00032. [Google Scholar] [CrossRef]
Rank | Authors | Journal | Publication Year | Total Citations | Citation Rate |
---|---|---|---|---|---|
1 | Fredriksson et al. [106] | Dermatologica | 1978 | 2145 | 49 |
2 | Nestle et al. [66] | New England Journal of Medicine | 2009 | 2041 | 157 |
3 | Parisi et al. [48] | Journal of Investigative Dermatology | 2013 | 1507 | 167 |
4 | Zheng et al. [62] | Nature | 2007 | 1450 | 97 |
5 | Boehncke et al. [81] | Lancet | 2015 | 1338 | 191 |
6 | Langley et al. [103] | New England Journal of Medicine | 2014 | 1337 | 167 |
7 | Gelfand et al. [102] | JAMA—Journal of The American Medical Association | 2006 | 1337 | 84 |
8 | Van der Fits et al. [54] | Journal of Immunology | 2009 | 1290 | 99 |
9 | Lowes et al. [72] | Nature | 2007 | 1291 | 86 |
10 | Griffiths et al. [85] | Lancet | 2007 | 1244 | 83 |
11 | Leonardi et al. [41] | Lancet | 2008 | 1237 | 88 |
12 | Parrish et al. [77] | New England Journal of Medicine | 1974 | 1296 | 27 |
13 | Papp et al. [40] | Lancet | 2008 | 1105 | 79 |
14 | Rapp et al. [89] | Journal of The American Academy of Dermatology | 1999 | 1078 | 47 |
15 | Nair et al. [47] | Nature Genetics | 2009 | 1010 | 78 |
16 | Lowes et al. [56] | Annual Review of Immunology, Vol 3 | 2014 | 918 | 115 |
17 | Leonardi et al. [44] | New England Journal of Medicine | 2003 | 934 | 49 |
18 | Schon et al. [67] | New England Journal of Medicine | 2005 | 877 | 52 |
19 | Reich et al. [60] | Lancet | 2005 | 847 | 50 |
20 | Cargill et al. [17] | American Journal of Human Genetics | 2007 | 843 | 56 |
21 | Nestle et al. [78] | Journal of Experimental Medicine | 2005 | 812 | 48 |
22 | Tyring et al. [42] | Lancet | 2006 | 825 | 52 |
23 | Lowes et al. [96] | Journal of Investigative Dermatology | 2008 | 776 | 55 |
24 | Papp et al. [25] | New England Journal of Medicine | 2012 | 743 | 74 |
25 | Krueger et al. [110] | Archives of Dermatology | 2001 | 786 | 37 |
26 | Leonardi et al. [22] | New England Journal of Medicine | 2012 | 733 | 73 |
27 | Di Cesare et al. [109] | Journal of Investigative Dermatology | 2009 | 780 | 60 |
28 | Wolk et al. [52] | European Journal of Immunology | 2006 | 727 | 45 |
29 | Neimann et al. [80] | Journal of The American Academy of Dermatology | 2006 | 739 | 46 |
30 | Strange et al. [15] | Nature Genetics | 2010 | 747 | 62 |
31 | Lee et al. [57] | Journal of Experimental Medicine | 2004 | 689 | 38 |
32 | Chaudhari et al. [39] | Lancet | 2001 | 724 | 34 |
33 | Menter et al. [21] | Journal of The American Academy of Dermatology | 2008 | 677 | 48 |
34 | Krueger et al. [18] | New England Journal of Medicine | 2007 | 617 | 41 |
35 | Tsoi et al. [49] | Nature Genetics | 2012 | 661 | 66 |
36 | Henseler et al. [92] | Journal of The American Academy of Dermatology | 1985 | 660 | 18 |
37 | Christophers [86] | Clinical And Experimental Dermatology | 2001 | 623 | 30 |
38 | Griffiths et al. [30] | New England Journal of Medicine | 2010 | 634 | 53 |
39 | Lin et al. [65] | Journal of Immunology | 2011 | 627 | 57 |
40 | Marrakchi et al. [63] | New England Journal of Medicine | 2011 | 610 | 55 |
41 | Nograles et al. [108] | British Journal of Dermatology | 2008 | 611 | 44 |
42 | Langley et al. [98] | Annals of The Rheumatic Diseases | 2005 | 607 | 36 |
43 | Arican et al. [105] | Mediators of Inflammation | 2005 | 594 | 35 |
44 | Sonkoly et al. [68] | Plos One | 2007 | 577 | 38 |
45 | Detmar et al. [71] | Journal of Experimental Medicine | 1994 | 584 | 21 |
46 | Griffiths et al. [29] | Lancet | 2015 | 592 | 85 |
47 | Sano et al. [107] | Nature Medicine | 2005 | 544 | 32 |
48 | Papp et al. [16] | British Journal of Dermatology | 2005 | 573 | 34 |
49 | Mcinnes et al. [38] | Lancet | 2013 | 561 | 62 |
50 | Hammarstrom et al. [55] | Proceedings of The National Academ | 1975 | 581 | 12 |
51 | Mrowietz et al. [33] | Archives of Dermatological Research | 2011 | 550 | 50 |
52 | Stern et al. [91] | Journal of Investigative Dermatology | 2004 | 558 | 31 |
53 | Saurat et al. [43] | British Journal of Dermatology | 2008 | 550 | 39 |
54 | Lebwohl et al. [75] | New England Journal of Medicine | 2015 | 539 | 77 |
55 | Rendon et al. [94] | International Journal of Molecular Sciences | 2019 | 520 | 173 |
56 | Chan et al. [53] | Journal of Experimental Medicine | 2006 | 510 | 32 |
57 | Stern et al. [101] | New England Journal of Medicine | 1979 | 544 | 13 |
58 | Rachakonda et al. [95] | Journal of The American Academy of Dermatology | 2014 | 535 | 67 |
59 | Lebwohl [84] | Lancet | 2003 | 498 | 26 |
60 | Gordon et al. [76] | New England Journal of Medicine | 2016 | 517 | 86 |
61 | Gottlieb et al. [100] | Nature Medicine | 1995 | 507 | 19 |
62 | Hollox et al. [90] | Nature Genetics | 2008 | 508 | 36 |
63 | Michalek et al. [20] | Journal of The European Academy of Dermatology and Venereology | 2017 | 481 | 96 |
64 | Pathirana et al. [46] | Journal of The European Academy of Dermatology and Venereology | 2009 | 507 | 39 |
65 | Henseler et al. [34] | Journal of The American Academy of Dermatology | 1995 | 500 | 19 |
66 | Wada et al. [24] | Plos One | 2012 | 492 | 49 |
67 | Ellis et al. [32] | JAMA—Journal of The American Medical Association | 1986 | 503 | 14 |
68 | Kagami et al. [27] | Journal of Investigative Dermatology | 2010 | 462 | 39 |
69 | Blauvelt et al. [36] | Journal of The American Academy of | 2017 | 493 | 99 |
70 | Takeshita et al. [87] | Journal of The American Academy of | 2017 | 472 | 94 |
71 | Nickoloff et al. [99] | Journal of Clinical Investigation | 2004 | 415 | 23 |
72 | Davidovici et al. [88] | Journal of Investigative Dermatology | 2010 | 477 | 40 |
73 | Sommer et al. [58] | Archives of Dermatological Research | 2006 | 477 | 30 |
74 | Abrams et al. [31] | Journal of Clinical Investigation | 1999 | 469 | 20 |
75 | Sugiyama et al. [35] | Journal of Immunology | 2005 | 444 | 26 |
76 | Ma et al. [51] | Journal of Clinical Investigation | 2008 | 451 | 32 |
77 | Stern et al. [64] | New England Journal of Medicine | 1997 | 487 | 19 |
78 | Mehta et al. [74] | European Heart Journal | 2010 | 488 | 41 |
79 | Ellis et al. [113] | New England Journal of Medicine | 2001 | 461 | 22 |
80 | Melski et al. [70] | Journal of Investigative Dermatology | 1977 | 483 | 11 |
81 | Gisondi et al. [82] | British Journal of Dermatology | 2007 | 468 | 31 |
82 | Kurd et al. [112] | Archives of Dermatology | 2010 | 474 | 40 |
83 | Zenz et al. [97] | Nature | 2005 | 442 | 26 |
84 | Hawkes et al. [93] | Journal of Allergy And Clinical Immunology | 2017 | 441 | 88 |
85 | Gelfand et al. [79] | Archives of Dermatology | 2005 | 446 | 26 |
86 | Krueger et al. [111] | Journal of The American Academy of Dermatology | 2002 | 431 | 22 |
87 | Lebwohl et al. [19] | New England Journal of Medicine | 2003 | 449 | 24 |
88 | Naldi et al. [26] | Journal of Investigative Dermatology | 2005 | 457 | 27 |
89 | Gottlieb et al. [59] | Journal of The American Academy of Dermatology | 2004 | 439 | 24 |
90 | Farber et al. [69] | Dermatologica | 1974 | 457 | 10 |
91 | Homey et al. [114] | Journal of Immunology | 2000 | 421 | 19 |
92 | Chiricozzi et al. [61] | Journal of Investigative Dermatology | 2011 | 437 | 40 |
93 | Greb et al. [83] | Nature Reviews Disease Primers | 2016 | 424 | 71 |
94 | Armstrong et al. [73] | JAMA-Journal of The American Medical Association | 2020 | 421 | 211 |
95 | Reich et al. [37] | Journal of The American Academy of Dermatology | 2017 | 420 | 84 |
96 | Nair et al. [104] | American Journal of Human Genetics | 2006 | 418 | 26 |
97 | Trembath et al. [50] | Human Molecular Genetics | 1997 | 410 | 16 |
98 | Gordon et al. [28] | Journal of The American Academy of Dermatology | 2006 | 405 | 25 |
99 | Baker et al. [45] | British Journal of Dermatology | 1968 | 420 | 8 |
100 | Nickoloff et al. [23] | American Journal of Pathology | 1991 | 406 | 13 |
Rank | Author | Articles | Total Citations |
---|---|---|---|
1 | Griffiths, CEM | 12 | 9646 |
2 | Krueger, JG | 12 | 7669 |
3 | Papp, K | 11 | 8944 |
4 | Krueger, GG | 10 | 7492 |
5 | Menter, A | 10 | 6945 |
6 | Langley, RG | 8 | 5747 |
7 | Lebwohl, M | 8 | 6318 |
8 | Nestle, F | 8 | 6779 |
9 | Gottlieb, A | 7 | 4080 |
10 | Reich, K | 7 | 5026 |
Rank | Journal | Total Articles | Total Citations | 2021 Impact Factor | 5-Year Impact Factor | Average Citations/Publication |
---|---|---|---|---|---|---|
1 | New England Journal of Medicine | 16 | 12,817 | 176.08 | 125.16 | 801.06 |
2 | Journal of The American Academy of Dermatology | 12 | 6847 | 15.48 | 12.07 | 570.58 |
3 | Lancet | 10 | 8966 | 202.73 | 130.84 | 896.6 |
4 | Journal of Investigative Dermatology | 8 | 5377 | 7.59 | 8.38 | 672.13 |
5 | British Journal of Dermatology | 5 | 2623 | 11.11 | 9.29 | 524.6 |
6 | Nature Genetics | 4 | 2926 | 41.37 | 39.32 | 731.5 |
7 | Journal of Immunology | 4 | 2782 | 5.43 | 6.17 | 695.5 |
8 | Journal of Experimental Medicine | 4 | 2595 | 17.57 | 16.42 | 648.75 |
9 | Nature | 3 | 3183 | 69.5 | 63.58 | 1061 |
10 | JAMA—Journal of The American Medical Association | 3 | 2257 | 157.37 | 101.12 | 752.33 |
11 | Archives of Dermatology | 3 | 1706 | 4.78 | 4.45 | 568.67 |
12 | Journal of Clinical Investigation | 3 | 1335 | 19.47 | 19.23 | 445 |
13 | Dermatologica | 2 | 2602 | N/A | N/A | 1301 |
14 | American Journal of Human Genetics | 2 | 1260 | 11.04 | 12.87 | 630 |
15 | Plos One | 2 | 1069 | 3.75 | 4.06 | 534.5 |
16 | Nature Medicine | 2 | 1051 | 87.24 | 68.31 | 525.5 |
17 | Archives of Dermatological Research | 2 | 1025 | 3.03 | 3.19 | 512.5 |
18 | Journal of The European Academy of Dermatology and Venereology | 2 | 987 | 9.22 | 7.72 | 493.5 |
19 | Annual Review of Immunology, Vol 32 | 1 | 917 | 32.48 | 35.19 | 917 |
20 | European Journal of Immunology | 1 | 726 | 6.68 | 6.09 | 726 |
21 | Clinical and Experimental Dermatology | 1 | 623 | 4.48 | 3.19 | 623 |
22 | Annals of The Rheumatic Diseases | 1 | 607 | 28 | 20.69 | 607 |
23 | Mediators of Inflammation | 1 | 594 | 4.52 | 5.6 | 594 |
24 | Proceedings of The National Academy of Sciences of The United States of | 1 | 581 | 12.77 | 13.45 | 581 |
25 | Journal of Investigative Dermatology Symposium Proceedings | 1 | 557 | 3.73 | 2.48 | 557 |
26 | International Journal of Molecular Sciences | 1 | 518 | 6.2 | 6.62 | 518 |
27 | European Heart Journal | 1 | 488 | 35.85 | 33.03 | 488 |
28 | Journal of Allergy and Clinical Immunology | 1 | 440 | 14.29 | 13.76 | 440 |
29 | Nature Reviews Disease Primers | 1 | 424 | 65.03 | 83.06 | 424 |
30 | Human Molecular Genetics | 1 | 410 | 5.12 | 5.99 | 410 |
31 | American Journal of Pathology | 1 | 406 | 5.77 | 5.48 | 406 |
Rank | Institution | Country | Articles | Citations | Total Link Strength |
---|---|---|---|---|---|
1 | Rockefeller University | USA | 13 | 8201 | 7 |
2 | University of Manchester | UK | 12 | 9788 | 11 |
3 | Probity Medical Research | Canada | 11 | 8223 | 11 |
4 | University of Michigan | USA | 10 | 5384 | 7 |
5 | University of Utah | USA | 10 | 7097 | 10 |
6 | Dalhousie University | Canada | 9 | 6354 | 9 |
7 | Harvard University | USA | 9 | 6605 | 8 |
8 | Penn University | USA | 9 | 5473 | 4 |
9 | Saint Louis University | USA | 8 | 6282 | 8 |
10 | Baylor University | USA | 7 | 4474 | 7 |
Rank | Keyword | No. of Occurrences | Cluster |
---|---|---|---|
1 | Quality of life | 17 | 1 |
2 | Skin | 15 | 3 |
3 | Therapy | 15 | 7 |
4 | Expression | 14 | 2 |
5 | Dendritic cells | 13 | 2 |
6 | Double-blind | 13 | 4 |
7 | Efficacy | 13 | 4 |
8 | Necrosis factor alpha | 13 | 5 |
9 | Rheumatoid arthritis | 12 | 1 |
10 | Safety | 10 | 4 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tiucă, O.M.; Morariu, S.H.; Mariean, C.R.; Tiucă, R.A.; Nicolescu, A.C.; Cotoi, O.S. Research Hotspots in Psoriasis: A Bibliometric Study of the Top 100 Most Cited Articles. Healthcare 2023, 11, 1849. https://doi.org/10.3390/healthcare11131849
Tiucă OM, Morariu SH, Mariean CR, Tiucă RA, Nicolescu AC, Cotoi OS. Research Hotspots in Psoriasis: A Bibliometric Study of the Top 100 Most Cited Articles. Healthcare. 2023; 11(13):1849. https://doi.org/10.3390/healthcare11131849
Chicago/Turabian StyleTiucă, Oana Mirela, Silviu Horia Morariu, Claudia Raluca Mariean, Robert Aurelian Tiucă, Alin Codruț Nicolescu, and Ovidiu Simion Cotoi. 2023. "Research Hotspots in Psoriasis: A Bibliometric Study of the Top 100 Most Cited Articles" Healthcare 11, no. 13: 1849. https://doi.org/10.3390/healthcare11131849
APA StyleTiucă, O. M., Morariu, S. H., Mariean, C. R., Tiucă, R. A., Nicolescu, A. C., & Cotoi, O. S. (2023). Research Hotspots in Psoriasis: A Bibliometric Study of the Top 100 Most Cited Articles. Healthcare, 11(13), 1849. https://doi.org/10.3390/healthcare11131849